SEC 8-K filings, insider trades, FDA approvals, Federal Reserve statements, and market-moving events — AI-curated, updated every 60 seconds.
Celcuity announced positive Phase 3 VIKTORIA-1 trial results showing gedatolisib combination regimens reduced disease progression risk by 50% compared to alpelisib in PIK3CA mutant…
Rezolute reported interim data from its Phase 3 upLIFT study of ersodetug in tumor hyperinsulinism, with 6 of 8 enrolled participants meeting the primary endpoint of 50% reduction …
Greenpro Capital Corp submitted an exhibit filing to the SEC. The document appears to be a standard regulatory filing with limited disclosed content details.
Black Rifle Coffee Company has regained compliance with NYSE minimum share price requirements after its Class A stock maintained at least $1.00 average closing price over a 30-day …
Genco Shipping & Trading Limited filed a third amendment to its shareholders rights agreement, removing the defined term "Acting in Concert" and revising the "Acquiring Person" thr…
The company identified a miscalculation in weighted average shares outstanding that overstated EPS by $0.02 for the quarter and $0.01 for nine months, with no impact on underlying …
TXNM Energy's Texas subsidiary TNMP filed a settlement agreement with the Public Utility Commission of Texas maintaining a 9.65% return on equity and 45% equity ratio, while recove…
The SPAC faces substantial doubt about its ability to continue operations without completing a business combination by May 14, 2027. The company lacks sufficient capital and has no…
BurTech Acquisition Corp II filed audited financial statements for May 26, 2026. Auditors raised substantial doubt about the company's ability to continue as a going concern due to…
The company filed an exhibit containing revised corporate governance documents. This is a routine regulatory filing with no immediate operational or financial impact.
Grant Thornton LLP confirmed it reviewed and agrees with statements in MaxLinear's Form 8-K Item 4.01 disclosure dated May 28, 2026 regarding an auditor change. This represents a r…
Beyond Air received approval from the Nasdaq Hearings Panel to maintain its listing on the exchange, contingent on regaining compliance with the minimum bid price rule by July 31, …
Citius Oncology presented Phase 1 data at ASCO showing LYMPHIR combined with pembrolizumab achieved 24% overall response rate and 48% clinical benefit rate in heavily pre-treated g…
Citius Oncology highlighted Phase 1 data for LYMPHIR combined with pembrolizumab showing 24% overall response rate and 20.5 months median progression-free survival in heavily pre-t…
Gencor Industries received a delinquency notification from NYSE Regulation on May 19, 2026 for failing to timely file its Form 10-Q for the quarter ended March 31, 2026. The compan…
IDEAYA Biosciences announced primary results from the OptimUM-02 trial evaluating darovasertib combined with crizotinib as first-line treatment for HLA-A2 negative metastatic uveal…
aTyr Pharma released an investor presentation outlining advancement of efzofitimod, its tRNA synthetase-derived therapeutic candidate, for pulmonary sarcoidosis and additional indi…
New Jersey Natural Gas submitted filings providing 8.9% bill savings ($158 annually per residential customer) for winter 2026-2027 while seeking base rate increases of 12.7% to rec…
Spectral AI announced FDA De Novo Classification for its DeepView System for burn wound assessment, authorizing commercial distribution in the U.S. The company also secured $31.7 m…
Oruka Therapeutics and Paragon Therapeutics executed a first amendment to their IL-23 license agreement dated May 29, 2026, expanding the Field definition from inflammatory bowel d…